4th Quarter - Termination
VENN STRATEGIES for AVANIR PHARMACEUTICALS, INC.
Firm
Client
Income
$20,000
Expenses
—
Terminated
Nov 15, 2022
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials.
Foreign entity interest: Ownership
| Lobbyist | Covered position, as disclosed |
|---|---|
| GRANT COUCH | — |
| MICHAEL SPIRA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.